会议报告:为预防宫颈癌而许可治疗性HPV16/18疫苗的试验设计与终点考虑
2023年9月12日至13日在华盛顿特区召开会议,讨论治疗性HPV16/18疫苗用于治疗现患HPV感染或宫颈癌前病变的试验设计与监管路径。报告汇总了研究现状、WHO首选产品特性、建模影响、HPV自然史与免疫应答及伦理考虑,并提出纳入排除标准、终点、样本量、安全性、研究时长等建议,指出需进一步研究HPV自然史以弥补监管指南空白。
要点
- 治疗性HPV疫苗旨在清除或控制致癌HPV及/或诱导癌前病变消退,可助力消除宫颈癌。
- 会议针对治疗现患HPV感染和治疗宫颈癌前病变两个适应症提出试验设计建议。
- 讨论涵盖纳入排除标准、研究终点、样本量、安全性、研究时长及所需额外数据。
核心结论
- 治疗性HPV疫苗的开发与许可可显著促进宫颈癌消除,尤其惠及错过预防性疫苗的女性,但需进一步研究HPV自然史以弥补监管指南空白。
研究设计与样本
- 2023年9月12日至13日在华盛顿特区召开会议,通过专家报告和小组讨论形成试验设计建议。
主要发现
- 专家报告涵盖研究现状、监管挑战、WHO首选产品特性、疫苗实施影响的建模结果、HPV感染流行病学与自然史、病毒清除及癌前病变消退相关免疫应答与潜在生物标志物、伦理考虑。
- 小组讨论针对治疗现患HPV感染和治疗宫颈癌前病变两个疫苗适应症,探讨了纳入排除标准、研究终点、样本量与把握度、安全性、研究时长及所需额外数据。
关键数值与推荐
- 会议提出支持许可过程的试验设计建议,涉及两个疫苗适应症:治疗现患HPV感染或治疗宫颈癌前病变。
- 讨论涵盖纳入排除标准、研究终点、样本量与把握度、安全性、研究时长及所需额外数据。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 需进一步研究HPV自然史以弥补监管指南中已识别的空白,尤其是针对治疗现患HPV感染的治疗性疫苗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cervical cancer is a major cause of morbidity and mortality globally with a disproportionate impact on women in low- and middle-income countries. In 2021, the World Health Organization (WHO) called for increased vaccination, screening, and treatment to eliminate cervical cancer. However, even with widespread rollout of human papillomavirus (HPV) prophylactic vaccines, millions of women who previously acquired HPV infections will remain at risk for progression to cancer for decades to come. The development and licensing of an affordable, accessible therapeutic HPV vaccine, designed to clear or control carcinogenic HPV and/or to induce regression precancer could significantly contribute to the elimination efforts, particularly benefiting those who missed out on the prophylactic vaccine. One barrier to development of such vaccines is clarity around the regulatory pathway for licensure. In Washington, D.C. on September 12-13, 2023, a meeting was convened to provide input and guidance on trial design with associated ethical and regulatory considerations. This report summarizes the discussion and conclusions from the meeting. Expert presentation topics included the current state of research, potential regulatory challenges, WHO preferred product characteristics, modeling results of impact of vaccine implementation, epidemiology and natural history of HPV infection, immune responses related to viral clearance and/or precancer regression including potential biomarkers, and ethical considerations. Panel discussions were held to explore specific trial design recommendations to support the licensure process for two vaccine indications: (1) treatment of prevalent HPV infection or (2) treatment of cervical precancers. Discussion covered inclusion/exclusion criteria, study endpoints, sample size and power, safety, study length, and additional data needed, which are reported here. Further research of HPV natural history is needed to address identified gaps in regulatory guidance, especially for therapeutic vaccines intended to treat existing HPV infections.
引用
- Dull PM, Achilles SL, Ahmed R, et al. Meeting report: Considerations for trial design and endpoints in licensing therapeutic HPV16/18 vaccines to prevent cervical cancer. Vaccine. 2024. PMID: 39004526. doi:10.1016/j.vaccine.2024.07.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。